CIK 0001937653 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 106.0 M | 412.5 M | ||
| Net income (USD) | 124.3 M | -211.8 M | -180.6 M | |
| Diluted EPS (USD/shares) | -1.08 | 1.9 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | PRE 14A | PRE 14A | 2026-12-15 |
| 2026-10-09 | 4 | FORM 4 | 2026-10-09 |
| 2026-10-09 | 144 | 144 | |
| 2026-09-23 | 8-K | 8-K items 1.01,2.01,2.03,7.01,9.01 | 2026-09-23 |
| 2026-08-25 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-08-25 |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-08-06 |
| 2026-07-06 | 4 | FORM 4 | 2026-07-06 |
| 2026-06-29 | 8-K | 8-K items 1.01,7.01,9.01 | 2026-06-28 |
| 2026-05-15 | 4 | 4 | 2026-05-13 |
| 2026-05-15 | 3 | 3 | 2026-05-13 |
| 2026-05-15 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-05-14 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-05-14 |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-07 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-05-07 |
| 2026-04-15 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-04-10 | 4 | 4 | 2026-04-09 |
| 2026-04-10 | 4 | 4 | 2026-04-09 |
| 2026-04-10 | 3 | 3 | 2026-04-09 |
| 2026-04-10 | 3 | 3 | 2026-04-09 |
| 2026-04-07 | 4 | 4 | 2026-04-06 |
| 2026-04-07 | 3 | 3 | 2026-04-01 |
| 2026-04-01 | 8-K | 8-K items 5.02,9.01 | 2026-03-31 |
| 2026-03-06 | 144 | 144 | |
| 2026-03-02 | S-8 | S-8 |
Forms on file (last 1,000): 4 94, 8-K 78, 144 22, 3 21, SC 13G/A 15, 10-Q 12, SCHEDULE 13G/A 9, 424B5 8. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ZYME (0.002 USD), /gw/filings/filings?ticker=ZYME&form=8-K, /gw/filings/facts?ticker=ZYME&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange